The U.S. Food and Drug Administration (FDA) has granted an emergency use authorization (EUA) to PathogenDx for the company's microarray-based COVID-19 test, DetectX-Rv.
DetectX-Rv is a reverse transcription polymerase chain reaction (RT-PCR) and DNA microarray test that uses material from nasopharyngeal, oropharyngeal, midturbinate, and anterior nasal swabs, as well as nasal aspirates, nasopharyngeal wash/aspirates, and bronchoalveolar lavage specimens from patients with suspected COVID-19, according to the firm.
